Sharekhan's research repor on Zydus Wellness
We expect the company to report revenue and earnings CAGR of 8.7% and 20%, respectively, during FY2020-2022E. Management eyes revenue growth of 6-8%, EBITDA growth of 10-12% and net debt-equity ratio of 2x during FY2021E. Q1FY21 revenue fell by 1% as volumes sold stayed unchanged, adjusted EBITDA margin improved by 508 bps to 21.8%; adjusted PAT increased by 70.7%.
Outlook
We stick to our Buy rating on UPL Limited (UPL) with a revised price target of Rs. 550.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
Read More
